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  April 2020      
  
BACKGROUND Lysosomes are acidic organelles responsible for recycling of 
metabolic byproducts and cellular debris, and there are approximately 60 
enzymes within lysosomes responsible for the recycling process.  These 
enzymes can be malfunctional due to genetic mutations, which results in a 
lysosomal storage disease (LSD). One of these diseases is 
aspartylglucosaminuria (AGU) caused by an incorrectly folded 
aspartylglucosaminidase (AGA) enzyme, which results in a buildup of the 
substrate aspartylglucosamine. This enzymatic deficiency impairs the cellular 
function in both central nervous system (CNS) and periphery manifesting as 
an impaired physical and mental development.  
UNMET MEDICAL NEED Currently, there are no curative or even symptom 
alleviating treatments available.  
AIM The aim of this research was to establish a reliable in vitro model of LSD 
to enable repeatable experiments for drug development purposes.  
MATERIALS AND METHODS Two cell types from an AGU patient and an 
age- and gender matched healthy individual were characterized. 
Characterization included enzyme activity and aspartylglucosamine 
concentration measurements, Western Blot studies and immunofluorescent 
stainings.  
RESULTS The study showed significantly higher AGA activity in the healthy 
cells when compared to AGU cells, and the protein expression analysis 
revealed more of the precursor form of AGA in AGU cells. In line with this 
finding, aspartylglucosamine concentration was significantly higher in AGU 
cells. In addition, when AGU cells were treated with AGA, the enzyme activity 
could be replenished and aspartylglucosamine concentration normalized.  
CONCLUSION Based on these measurements, an in vitro baseline for AGU 
and a healthy control is now established for future studies.  
Key Words: Lysosomal storage diseases, aspartylglucosaminuria  
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2. Review of literature  
  
2.1 Lysosomes   
  
Lysosomes, first described in the 50s (De Duve et al, 1955), are small, acidic 
cell organelles of approximately 200-500 nm in size under normal conditions 
(Alberts et al, 2015). These acidic compartments have a resting [Ca2+] of about 
500 µM, which is 5000-fold higher compared with the cytosolic [Ca2+] of 100 
nM but over 10 000 times smaller than extracellular [Ca2+]. From these 
intracellular storages, calcium is released through different calcium-channels, 
which are located within the lysosomal membrane (Christensen et al, 2002). 
Thus, lysosomes act as important intracellular calcium storages - which is the 
most common second messenger regulating various cellular functions from 
cellular growth and cell cycle to apoptosis. (Feng & Yang, 2016)   
Lysosomes are rich in hydrolases that are responsible for the degradation of 
cellular biomaterial and different macromolecules, such as complex lipids and 
oligosaccharides, into reusable building blocks. After breakdown, these 
catabolites are transported into the cytosolic compartment and used by the cell 
in various metabolic reactions. (Bainton, 1981) In addition to the degrading 
function, lysosomes are regulators of receptor availability; they sense the need 
of nutrients, and control cholesterol homeostasis, exocytosis and cell death. 
Availability of nutrients is an essential factor in cellular homeostasis, which is 
regulated by activation of a crucial transcription factor, EB (TFEB). TFEB is 
described as the master regulator when it comes to genes regulating 
lysosomal function – indeed, TFEB is found to regulate at least 18 of the 23 
lysosomal genes tested by Sardiello et al, 2009. Not only does TFEB control 
purely genes regulating lysosomal function, but TFEB also regulates genes 
within the CLEAR-network (Coordinated Lysosomal Expression and 
Regulation, Sardiello et al, 2009). Genes within this network are a direct 
downstream targets of TFEB, and encode for example proteins on the 
lysosomal membrane (CLCN7, CLN3, TMEM55B), proteins responsible of the 
acidification of lysosomes (ATP6AP1, ATP6V0A1, ATP6V0B) and proteins 
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that are not directly associated with lysosomes, but have a regulative function 
associated with the lysosomal biogenesis (HPS1, NAGPA1, SUMF1) (Palmieri 
et al, 2011). In addition to these functions, the TFEB and the downstream 
CLEAR-network regulate the transcription of genes BECN1, GABARAP and 
SQSTM1, which are mediators of autophagosome-formation (Palmieri et al, 
2011; Kondratskyi et al, 2018). In conclusion of TFEB downstream targets, the 
master regulator of lysosomal function indeed orchestrates an elaborate 
system of lysosome-associated operations across the cell.  
 
Activation of TFEB results in its translocation to nucleus, where it regulates the 
transcription of lysosomal genes resulting in, for example, activation of 
autophagy or lysosomal biogenesis. TFEB is activated through abnormal 
lysosomal function, such as extensive accumulation of cellular debris. 
Activation of TFEB was demonstrated by Sardiello et al in 2009, when they 
discovered that overexpression of TFEB resulted in a significant reduction in 
the amount of mutant huntingtin compared to a control cell line. Huntingtin 
protein is mutated and thus accumulating in Huntington’s disease causing the 
pathology of the disease.  In addition to Huntington’s disease, activation of 
TFEB through lysosomal stress is present in other pathologies such as 
lysosomal storage diseases. In this group of diseases, the lysosomal stress is 
caused by abnormal lysosomal accumulation of macromolecules, which is the 
primary pathological process causing the disease.  
Upstream from TFEB is its regulator, mechanistic target of rapamycin (mTOR). 
Under normal conditions, TFEB is kept in its phosphorylated, inactive form by 
mTOR residing on close proximity of lysosomes. This is crucial in order to 
respond to the changing circumstances within the lysosomes, for instance, to 
nutrient deprivation. If starvation, for example, occurs, mTOR separates from 
the lysosome resulting in the dephosphorylation of TFEB by calcineurin, 
activating the transcription factor followed by the relocation of TFEB to the 
nucleus and promotion of transcription of genes in response. (Bai et al, 2007) 
Although a very interesting signaling route connecting pathologies associated 
with lysosomes with pathologies affecting central nervous system (CNS), this 
literature review will not cover the specificities of the mTOR-TFEB route.   
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As the activation of lysosome biogenesis is initiated, there are several 
predecessors before the membrane coated organelles with acidic lumen are 
ready. Thus, there are several cytosolic organelles that resemble lysosomes 
and are partly responsible of similar tasks as lysosomes. However, lysosomes 
are distinguished from other acidic organelles by the absence of both 
cationdependent and cation-independent mannose 6-phosphate receptors 
(MPRs). (Eskelinen et al, 2003) Rather than lysosomes, MPRs are associated 
with early and late endosomes (EE and LE, respectively), which precede 
lysosomes in the maturation pathway of these organelles. These receptors can 
be used to distinguish the stages of lysosomes in their maturation process. 
(Sapmaz et al, 2019) The maturation process initiated by the mTOR-TFEB 
route includes several individual cellular organelles before the lysosomes 
reach their classical acidic lumen filled with catabolizing hydrolases.   
  
2.1.1 Function and maturation   
  
Lysosome maturation is a dynamic process in which the lumen of membrane-
coated vesicular organelles acidifies towards the lysosomal pH. The 
predecessors of lysosomes have important functions in the cellular recycling 
process, and thus cannot be thought as passive predecessors but as active 
individual players. Thus, calling the acidification process a “maturation 
process” unnecessarily highlights lysosomes at the cost of the other players of 
this network, but since this thesis is focusing especially on lysosomes’ role in 
pathophysiology of lysosomal storage disease, the preceding steps are 
referred to as maturation process.  
 
Lysosome biogenesis process starts from the Trans-Golgi-Network (TGN), 
where lysosomal hydrolases and membrane proteins are synthetized. From 
there, MPRs are responsible for transferring the hydrolases tagged with 
mannose 6phosphate (M6P) into endosomes, where MPRs dissociate from 
their cargo and are recycled back to the TGN (Figure 1). However, it must be 
kept in mind that transportation of the molecules is not limited to MPRs and 
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can be done with the help of e.g. low-density lipoprotein receptor‐related 
protein, sortilin or LIMP2 (Hiesberger et al, 1998; Lefrancois et al, 2003; 
Reczek et al, 2007), depending on the transported protein in question and of 
the cell type. Thus, transportation of membrane proteins does not require 
binding of mannose 6-phosphate but can be reinforced by different proteins 
and accomplished either indirectly through plasma membrane or directly 
intracellularly. (Stoorvogel et al, 1991; Doray et al, 2002) Although several 
different alternative pathways for transportation to lysosomes have been 
described, M6P is still the main pathway of lysosomal transport and thus, will 
be looked into in more detail.  
 
Figure 1. The route of the lysosomal proteins from Trans-Golgi Network 
(TGN) to lysosomes either directly from TGN with the help of mannose-
6-phosphate (M6P) receptors or via the cellular membrane. The M6P 
tags help the proteins to be sorted correctly to lysosomes, but are 
themselves however cleaved by the acidification of the predecessors of 
lysosomes and recycled within the lysosomal protein synthesis process. 
Adapted from Schultz et al, 2011. 
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Transporting the lysosomal proteins to their intracellular destinations requires 
recognition signals. As briefly discussed in previous chapter, M6P and its 
receptor, MPR, are mainly responsible of the correct destination when 
transportation of lysosomal hydrolases and membrane proteins occurs. M6P 
is a unique marker for acid hydrolases destined to lysosomes, and this marker 
is added to the N-linked oligosaccharide chain that has a specific recognition 
signal, a specific group of nearby amino acids. (Alberts et al, 2015) Thus, not 
only a passive membrane protein used as a lysosome maturation indicator, 
M6Ps are heavily responsible of protein transportation to the lysosomes. 
(Reitman & Kornfeld, 1981) M6Ps are added to the lysosomal proteins during 
their production and maturation while they are transported from endoplasmic 
reticulum (ER) to TGN, after which the newly synthetized signal peptide is 
revealed in TGN. (Rohrer & Kornfeld, 2001) MPRs recognize M6Ps and bind 
to them on the inside of the transport vesicles. On the cellular side of the 
vesicles, MPRs bind to the transport vesicle assembly proteins. This ensures 
that the lysosomal hydrolases inside transport vesicles are packaged to the 
right vesicles with a correct intracellular destination. The hydrolases transit to 
cellular organelles preceding lysosomes, after which the M6P-receptors 
dislodge from the enzymes. This dislodging is induced by the drop in pH when 
they reach the predecessors of lysosomes with a pH of 6, which is 
approximately 0.5 lower than in the TGN. (Alberts et al, 2015) The MPRs are 
recycled back to TGN for their next cargo or relocated onto the cell surface, 
depending on their subtype.  
MPRs can be divided into two different classes depending on their 
cationdependency when binding the M6Ps – to cation-dependent MPR (CD-
MPR) and cation-independent MPR (CI-MPR). The CI-MPR can also be called 
insulin-like growth factor II -receptor (IGF-II-receptor) due to its ability to bind 
the IGFII as well. Only the cation-independent receptors relocate onto the cell 
surface in the recycling process of the receptors. These receptors relocating 
on the cell membrane are also responsible of capturing lysosomal hydrolases 
that have escaped the direct transportation route to the lysosomes and have 
instead been secreted to the extracellular space. There is, however, no harm 
in this extracellular detour, since the lysosomal hydrolases require an acidic 
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environment in order to be able to break down their substrate. Additionally, the 
cells have receptors for recapturing these circulating hydrolases. This 
relocation of the CI-MPRs onto the cellular surface provides the possibility to 
replenish the lysosomal enzyme depot with an extrinsically produced enzyme. 
This route is used in enzyme replacement therapy (ERT) where a functional 
enzyme is administered to the patients in order to restore the enzyme activity 
within the lysosomes. (Bajaj et al, 2019) Although seemingly a very straight-
forward pathway to restore the enzyme activity to an appropriate state to 
alleviate the pathologies, there are problems with this approach, such as the 
poor brain penetration of the enzyme due to the protective function of blood 
brain barrier (BBB). 
Although the M6P-route to lysosomes is addressed from the lysosomal point 
of view, the signal peptide is indeed cleaved before the cellular membrane-
coated vesicle is classified as a “mature” lysosome. The first stage after 
leaving the TGN, are the EEs. As the lysosomal maturation progresses, EE is 
not only a passive middle stage in the lysosome maturation process, but rather 
an active recycling center for endocytosed extracellular material. Majority of 
the endocytosed material is actively recycled via the plasma membrane or 
excreted into extracellular space.  (Kaur & Lakkaraju, 2018) 
As the heavily regulated active recycling of cellular waste and metabolic 
byproducts continues, traffic between endosomes and TGN is constant. As the 
endosome matures, the recyclable material gathered from within the cell is 
transported back into TGN. In the meantime, lysosomal molecules are 
constantly delivered to the opposite direction, to the maturing late endosome. 
Late endosome is characterized by acidic hydrolases in the lumen and 
expression of lysosomal membrane proteins, e.g. Lysosome-associated 
Membrane Protein-1 (LAMP-1) (Bucci et al, 2000). Fusing with lysosomes, 
either fully or through “kiss-and-run” fusion, turns the late endosome either into 
an endolysosome or directly into a lysosome. These fusions require Ca2+ 
release, in a similar manner than lysosomal exocytosis when fusing with the 
cellular plasma membrane. Lysosomes have transmembrane calcium 
channels to fulfil this task, as mentioned before (Pryor et al, 2000; Christensen 
et al, 2002). Transformation between the maturation forms is not exact as the 
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maturation process is highly dynamic. However, a distinctive differentiation 
between the forms can be made in the descending pH value as the endosomes 
transform from early endosomes to late endosome and further into lysosomes 
through endolysosomes.   
The pH drops from over 6 (EE), being 6-4.8 in LE and reaching as low as 4.5 
in lysosomes. (Maxfield and Yamashiro, 1987) In addition to helping the 
hydrolysis process, acidic environment contributes to the trafficking of 
membrane molecules, pathogen inactivation and recycling process. Acidic 
environment and pH differences between the maturation stages of the 
organelles is maintained by ATP-dependent vacuolar proton pump (V-
ATPase). V-APTases are transmembrane proteins that regulate the proton 
influx and they consist of different subunits. Thus, the activation stage of V-
ATPases depends on the subunit activation, which changes through the 
maturation stages causing descending pH. (Trombetta et al, 2003; Lafourcade 
et al, 2008, Schwake et al, 2013)  
 
Due to the highly acidic lumen of lysosomes and several degrading enzymes 
residing within the lysosomes, the lysosomal membrane is a crucial structure 
for protecting the cytosol from the hydrolases. In addition, the fusion with other 
organelles and cellular membrane requires regulatory proteins residing on the 
membrane of the vesicles. Often glycosylated, these membrane proteins are 
responsible for maintaining the lysosomal lumen intact and controlling the 
transport across the membrane. The most abundant proteins on the lysosomal 
membrane are the lysosomal associated membrane protein LAMP-1 together 
with LAMP-2. In addition to these, TRPML1, CLN3 and sialin, for example, are 
all located on the lysosomal membrane and play a role in lysosomal function. 
(Ruivo et al, 2009) Pathological states manifesting from a misfolded 
membrane protein prove the important role of these proteins. For example, 
Niemann-Pick disease type C has been linked with abnormally glycosylated 
LAMP-1 (Cawley et al, 2020), whereas LAMP-2 deficiency causes Danon 
disease (Nishino et al, 2000). Lastly, mucolipidosis type IV is caused by a 
mutation in the gene coding for TRPML1 cation channel on lysosomal 
membrane (Sun et al, 2000).  
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The function of lysosomal membrane proteins varies greatly. For instance, 
LAMPproteins have been shown to play a role in autophagic machinery, 
cholesterol trafficking, transportation of cytosolic peptides for degradation and 
lysosomal biogenesis. (Eskelinen et al, 2004; Demirel et al, 2012) TRPML1, 
on the other hand, plays a part in Ca2+ release from the lysosomes when 
autophagic machinery is activated. This machinery is discussed in the next 
chapter from lysosomes’ point of view. The Ca2+ release from the lysosomes 
marks the start of the autophagic process, which in turn activates downstream 
proteins responsible for upregulation of autophagy-related genes. (Medina et 
al, 2015)  
  
2.1.2 Lysosomes’ role in autophagy  
  
Autophagy is a well-preserved catabolic process where biomolecules are 
transported into lysosomes and degraded into building blocks to be used again 
in the cell. Autophagic pathway is parallel to the lysosomal maturation 
pathway, where intracellular material is transferred to lysosomes through 
autophagy. Autophagy is a vital process in, for example, adaptation to nutrient 
deprivation during starvation, anti-aging, preventing neurodegeneration, 
regulating immune response and tumor suppression. (Settembre and Ballabio, 
2011) Not only is the lysosomal function impaired in lysosomal storage 
diseases, but also autophagic machinery is damaged (Spampanato et al, 
2013).   
Autophagy can be divided into three different types: microautophagy, 
chaperone-mediated autophagy and macroautophagy. Microautophagy refers 
to a process where lysosomal membrane invaginates transferring cytosol into 
the lysosome, whereas chaperone-mediated autophagy means 
transmembrane trafficking of cytosolic proteins into the lysosomes. 
(Mizushima et al, 2010) Macroautophagy is the most studied form of 
autophagy and the focus of this chapter. Hence, hereafter, macroautophagy 
will be referred to as autophagy.  
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When autophagy is stimulated by, for example starvation as discussed before, 
activated dephosphorylated TFEB relocates from the cytosol into the nucleus 
inducing DNA transcription of multiple genes. TFEB activation requires 
upstream activation of calcineurin, which responds to Ca2+ efflux from 
lysosomes via TRPML1 (Medina et al, 2015). Translocation of TFEB to 
nucleus causes a chain reaction culminating in the formation of double-
membrane vesicles within the cytoplasm. These autophagosomes fuse with 
lysosomes creating an autolysosome. (Ravikumar et al, 2010; Settembre et al, 
2013)   
In addition to numerous proteins, this fusion also requires lysosomal 
acidification. For example, inhibition of V-ATPase by bafilomycin, has been 
shown to inhibit the fusion of autophagosomes and lysosomes (Yamamoto et 
al, 1998). This inhibition route can be used in in vitro research of autophagy. 
On the contrary, upregulating autophagy can be accomplished through 
starvation or, for example, with rapamycin treatment, which inhibits mTOR and 
releases TFEB to relocate to the nucleus. (Ravikumar et al, 2004) Impaired 
autophagy, with a defect in either autophagosome creation or the fusion with 
lysosomes, in addition to impaired lysosomal function, might cause the 
symptoms of lysosomal storage diseases discussed later.   
In conclusion, autophagy is a crucial process rapidly responding to intracellular 
stress arising from e.g. starvation and being orchestrated by the vast TFEB-
regulated network. This response depends on the acidic lumen of lysosomes 
that is utilized in the fusion with autophagosomes and is crucial for the 
catabolizing hydrolases to work. Not only do lysosomes exploit acidic 
environment and hydrolases for degradation, but they can also discard 
metabolic byproducts and other cellular waste by exocytosis. Exocytosis is a 
process which allows the cell to secrete the cellular waste possibly too 
complex to metabolize. The two-step process culminates in a fusion between 
lysosome and plasma membrane, after which the contents of lysosome are 
discarded in the extracellular space.  
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2.1.3 Lysosomal exocytosis  
  
Lysosomal exocytosis is a crucial cellular secretory pathway including Ca2+ 
independent and –dependent steps is a process of two sequential steps. In 
addition to secretion, this mechanism is crucial in repairing the plasma 
membrane of the cells. The same membrane-budding stages are also used 
intracellularly in the fusion of membrane-coated vesicles with each other, such 
as when lysosomes and endosomes fuse together. In normal, non-diseased 
conditions, for most cells, lysosomal exocytosis is only a minor exocytotic 
pathway, which is mainly used when cells are under stress. This was 
demonstrated in a study by Rodríguez et al conducted in 1997, where the 
group demonstrated an increase in lysosomal exocytosis in response to an 
increase in intracellular [Ca2+]. This increase in calcium concentration is a 
signal of cellular stress, to which TFEB dephosphorylation and thus activation 
responds to, climaxing in autophagy upregulation. As stated before, this 
exocytotic pathway can be divided into two sequential steps distinguished by 
their Ca2+ dependency.  
In the first, Ca2+ independent step, the lysosomes move to close proximity of 
the cell membrane with the help of Rab proteins that direct the vesicle towards 
its destination, and motor proteins that move the vesicles along microtubules 
or actin filaments of the cell cytoskeleton. There are over 60 known Rab 
proteins, which are all monomeric GTPases, and they work together with Rab 
effectors. (Alberts et al, 2015) The transport-location specific Rab proteins 
regulate the transportation of the vacuoles into the right place, including the 
cellular membrane, where the fusion and exocytosis occur. There are multiple 
different Rab proteins and effectors depending on the cell type. For example 
in melanocytes, the Rab27a associates with melanophilin and myosin Va and 
together this tri-protein complex is responsible of the transport of granules from 
microtubules to actin. (Bossi et al, 2005)  
The second step in the exocytosis is dependent of Ca2+ and involves fusion 
between the cellular membrane and lysosomes in order to empty the contents 
of lysosome outside the cell. Increase in the intracellular level of Ca2+ induces 
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lysosomal exocytosis, which follows employment of N-ethylmaleimide-
sensitive factor-attachment protein receptors (SNAREs) needed for lipid 
membrane fusions (Jaiswal et al, 2002). SNARE-complex and its regulators 
attach the lysosomes to the intracellular plasma membrane, after which 
localized increase in Ca2+ concentration induces exocytosis. (Rodríguez et al, 
1997)   
Lysosomal exocytosis is heavily controlled by different pathways within the 
cell. The before mentioned master controller of lysosomal function, TFEB, has 
been shown to affect multiple cellular processes involving lysosomes. For 
example, overexpression of TFEB increased both lysosome biogenesis and 
Ca2+ dependent exocytosis. (Saridello et al, 2009; Medina et al, 2011) Increase 
in exocytosis is explained by the regulatory role of TFEB: its downstream 
target, a cation channel on lysosomal membrane called TRPML1, releases 
calcium to trigger lysosomal exocytosis. When TFEB is overexpressed in cells 
depleted of TRPML1, intracellular Ca2+ concentration is not increased. 
(Medina et al, 2011)   
In addition to these abovementioned regulators of lysosomal function and the 
role of calcium, the subcellular localization of the lysosomes also affects the 
result of their activation. Exocytosis rate increases in those lysosomes 
proximal to the cellular membrane when Ca2+ concentration increases (Jaiswal 
et al, 2002). In addition to exocytosis regulation, it has also been demonstrated 
that increased Ca2+ concentration regulates autophagy, and various 
speculations of the mechanism have been published (Grotemeier et al, 2010; 
Bootman et al, 2018). Thus, this network with players such as intracellular 
calcium, the master regulator TFEB, and its downstream target genes is truly 
a maze that can only be briefly mentioned in this review.   
If exocytosis is to be studied, it can be observed by the expression of LAMP-1 
on the cell membrane following the lysosomal fusion with the plasma 
membrane, since LAMP-1 is only expressed on the lipid membrane of LEs and 
lysosomes and is exposed for the antibodies by the cellular plasma membrane. 
LAMP-1 together with LAMP-2 is the most abundantly expressed protein on 
the lysosomal membrane. (Saftig and Klumperman, 2009) Another protein that 
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can be detected in exocytosis is TRPML1, the cation channel increasing 
lysosomal Ca2+ efflux to trigger membrane fusion.    
Thus, exocytosis could be detected by the presence of LAMP-1 on the cellular 
plasma membrane after the fusion needed for exocytosis. This was evident on 
the cellular model overexpressing TFEB in the study conducted by Medina et 
al in 2011. Together with the LAMP-1 detection on cellular membrane, also 
several lysosome-specific enzymes can be detected from the cell culture 
medium and thus verify the rate of exocytosis.   
As a conclusion, TFEB has a crucial role in regulating both overall lysosomal 
function and autophagy, the cellular process used to dispose intracellular 
waste. Lysosomal degradation being the main waste disposal method for 
endocytosed molecular debris, autophagy is used for intracellular waste, such 
as misfolded proteins and worn-out cellular organelles. In case of bigger, non-
digestible molecules, the cells use exocytosis to dispose intracellular waste.  
Hypothetically, these processes could be utilized in repairing the cellular 
impairments caused by substance accumulation by enhancing the exocytosis 
or autophagy. These substance accumulation pathologies could be LSDs, but 
also CNS-affecting accumulation diseases such as Parkinson’s disease. 
Currently, no treatment exploiting lysosomal degradation and autophagy 
through modulating TFEB activation is in use in the clinics, although recently 
published studies suggest that these are under investigation. TFEB activation 
has been proposed to be of use in in vitro and in vivo parkinsonian 
neurotoxicity (Wang et al, 2020; Zhuang et al, 2020), in alleviating diabetic 
nephropathy both in vitro and in vivo (Yuan et al, 2020), and in treatment of 
Pompe disease (Spampanato et al, 2013). Pompe disease is one of the LSDs 
where glycogen accumulates due to inefficient acid alpha-glucosidase causing 
a severe myopathy (Spampanato et al, 2013). These storage diseases share 
common pathological processes discussed in the next chapter.   
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2.2 Lysosomal storage diseases   
  
First defined by Hers in 1963, lysosomal dysfunction causes macromolecules 
to accumulate progressively in cells, and this type of pathogenic conditions are 
classified as lysosomal storage diseases (LSDs) (Lieberman et al, 2012). 
LSDs are distinguished by an excessive buildup of metabolic byproducts, 
which negatively affects the homeostasis of lysosomes causing rupture of the 
acidic organelles into cytoplasm triggering cell death. This leads to dysfunction 
of different tissues and organs, which results in an often untreatable 
pathological state. (Boya and Kroemer, 2008; Parkinson-Lawrence et al, 2010) 
Accumulation of undigested metabolic byproducts causes the lysosomes to 
enlarge, which is a histological characteristic of LSD cells. There are over 70 
different LSDs collectively affecting approximately 1:7700 live births (Meikle et 
al, 1999). These diseases are orphan diseases caused by a mutation in a gene 
coding for an enzyme affecting lysosomal function (Samie and Xu, 2014). The 
mutated enzymes can be lysosomal hydrolases directly affecting lysosomal 
degradation of lipids, or proteins indirectly affecting lysosomal substrate 
degradation (Parkinson-Lawrence et al, 2010; Schulze and Sandhoff, 2010).   
LSDs are progressive diseases affecting multiple organs, especially tissues 
with significant amount of postmitotic cells. The usual symptoms, such as 
mental retardation, neurodegeneration and motoric disabilities manifest 
through the affected organs, including brain, liver, spleen, eye and muscle. 
LSDs often result in premature death after a decline in both physical and 
mental health usually arising from early childhood. (Samie and Xu, 2014; Platt, 
2018) Several therapeutic approaches have been developed for LSDs, which 
vary according to the specific disease pathology. Therapy options can be 
divided into two categories based on the target: disease specific therapies and 
therapies targeting downstream targets of the pathogenic cascade. Treatment 
options, regardless of the category, include bone marrow transplantation 
(BMT), ERT, gene therapy, small molecule chaperons and substrate reduction 
therapy (SRT). In BMT, the patient receives a bone marrow transplant from a 
healthy donor, after which enzymatically capable blood cells, e.g. 
macrophages, replace the patient’s own macrophages and contribute to 
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clearance of accumulated product. In addition, healthy cells obtained from the 
donor can repair enzyme function in cells through cross correction. This means 
enzyme exocytosis through the before mentioned extracellular detour and 
endocytosis of the circulating enzyme through MPRs. ERT exploits the same 
pathway, but in ERT, the working enzyme is given exogenously. (Macauley, 
2016) Gene therapy, on the other hand, aims to recover the enzyme function 
intrinsically by targeting the mutated gene with a viral vector delivering the 
correct sequence and thus repairing the mutation. (Sands and Davidson. 
2006) Chaperons are small molecules that bind to the readily translated protein 
chain and stabilize the correct folding structure, whereas substrate reduction 
therapy aims at the reduction of the substrate amount by small molecules that 
inhibit the synthesis rate of the accumulating substrate. (Macauley, 2016; 
Banning et al, 2016) Several different approaches have been developed and 
studied for LSD treatment. Available therapy options depend on the disease 
and range from several different options in Gaucher disease to no treatment 
options in aspartylglucosaminuria (AGU).   
Gaucher disease, an LSD caused by an impaired acid-𝛽-glucosidase function 
has the most approved treatment options available. There are five different 
U.S. Food and Drug Administration (FDA)-approved treatment options, of 
which the European Medicines Agency (EMA) approves four. The four EMA-
approved treatment options are imiglucerase (ERT), velaglucerase (ERT), 
miglustat (SRT) and eliglustat (SRT). In addition to Gaucher disease, several 
other LSDs’ have ERTs available, for example agalsidase-𝛼 for Fabry and 
alglucosidas alfa for Pompe disease. (Beck, 2017) Several other treatments 
have been granted the orphan drug designation status and will probably 
provide ease in the disease symptoms in several lysosomal storage diseases. 
Despite several treatments being granted marketing authorization, there is no 
curative treatment for any LSD available. Thus, the unmet medical need for 
both symptom alleviating treatment and curative treatment remains high.   
Although different diseases with unique pathology, all LSDs are lysosomal 
disorders affecting a wide range of tissues both in CNS and periphery. 
Evidently, the lysosomal function is one of the key mechanisms within the cell 
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regulating the homeostasis of catabolic and anabolic pathways. In LSDs, both 
lysosomal function and autophagy are impaired. (Spampanato et al, 2013)  
2.3 Aspartylglucosaminuria  
 
Aspartylglycosaminuria (AGU) is a lysosomal storage disease where 
aspartylglucosaminidase (AGA) activity is diminished. The lack of enzyme 
activity leads to accumulation and increased secretion of glycopeptides, 
particularly aspartylglucosamine (GlcNAc-Asn). (Dunder et al, 2000) Being 
part of the Finnish disease heritage, most of the disease cases can be found 
in Finland. The carrier rate is around 1:40, and the autosomal, recessively 
inherited disease incidence rate is about 1:18 000 (Norio, 2003).   
 
Figure 2. The cleavage of AGA into its subunits and transportation 
from ER to lysosome. SP=signaling peptide. Adapted from Kelo, 
2013. 
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Under normal conditions, AGA is synthetized in the ER, where it undergoes 
post-translational changes before autocatalytical cleavage into two subunits, α 
and β (Figure 2). These subunits form a heterotetramer, which is held together 
by noncovalent forces, constituting the active form of AGA enzyme. (Oinonen 
et al, 1995)  The newly formed heterotetramer (α2β2) is transferred to 
lysosomes after it is tagged with M6P, as discussed in chapter 4.1.1. After 
transportation to lysosomes, an additional cleavage occurs for the C-terminal 
ends of both subunits. However, this has no effect on the enzymatic activity 
but rather precedes an important step: formation of intrasubunit disulfide 
bridges between eight cysteine residues (McCormack et al, 1995; Riikonen et 
al, 1995). Formation of disulfide bonds is crucial for the stabilization of the 
enzyme and correct tertiary structure, and thus, for the function of AGA 
(Dunder, 2010).  
 
 AGA gene is located in chromosome 4q32-q33, where also the disease-
causing mutations are located. There are two mutations identified in Finnish 
population causing the disease: AGUFIN major and AGUFIN minor. (Norio, 2003) 
In the AGUFIN major, two point mutations in AGA have been found of which 
one causes the inactivity of glycosylasparagine, and this point mutation is 
responsible for 98% of the Finnish AGU patient cases. Thus, this founder 
mutation is termed AGUFIN major mutation. (Dunder, 2010) This major mutation 
is responsible of two amino acid substitutions, Arg161Gln and Cys163Ser. The 
latter serine is crucial for the formation of intramolecular disulfide bridges and 
thus, this substitution results in misfolded protein chain and an inactive 
enzyme, causing the accumulation of the aspartylglucosamine. The AGUFIN 
minor is a two base-pair deletion in the second exon of AGA causing a 
frameshift mutation resulting in premature termination of the translation. 
(Isoniemi et al, 1995) In addition to these two major mutations recognized to 
be in abundance in the Finnish individuals affected with AGU, more than 30 
different  mutations have been identified around the world. The other mutations 
affect the protein product in many ways, for example resulting in incorrect 
folding, incorrect cleavage of the proenzyme into its subunits, too early stop 
codon, or shift in reading frame. (Ikonen et al, 1991) What is common to all 
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these patients is impaired enzyme function of AGA and accumulation of its 
substrate. In addition, all the mutations are recessive and thus, from the 
disease pathology point of view, one copy of the correct gene coding for the 
enzyme is enough for the pathology to be absent. 
  
2.3.1 Clinical picture  
  
AGU can be diagnosed from urine, detecting the secreted 
aspartylglucosamine (Mononen et al, 1988). In addition, a DNA test can be 
done to confirm the disease from the mutations in AGA. Accumulation of the 
glycopeptides causes severe mental retardation, coarse facial features and 
premature aging (Arvio et al, 2004). In the childhood, patient has an 
abnormally slow but positive mental and psychomotor development. In years 
15-25, a stable state or slow decline in both mental and physical health is seen, 
followed by a steep decline after the plateau. Patients rarely live beyond 50 
years. One in three patients also suffer from epilepsy, twenty percent have an 
associated psychiatric disorder and five percent rheumatoid arthritis. (Arvio et 
al, 1993 & 1998)  
In recent years, studies on cognitive capabilities and brain structure of AGU 
patients have been conducted. Cognitive capabilities of AGU children remain 
significantly lower than in age-matched healthy controls. The AGU children 
studied, aged 7-14, did not reach the average developmental level of healthy 
6-year-old children. In addition, the developmental score did not improve with 
age, even if previous studies suggest a slow but positive learning curve for 
AGU children. (Arvio, 1993; Harjunen et al, 2020) In a brain MRI study 
conducted by Tokola et al in 2015 cerebellar or cerebral atrophy was found in 
almost all AGU patients investigated in addition with poor differentiation 
between grey and white matter, which was seen in all patients imaged. These 
studies highlight the cognitive impairment coupled with the disease 
progression in the CNS, which is caused by the neuronal damage thought to 
result from the accumulation of GlcNAc-Asn.  
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Although the clinical picture of the disease is somewhat characterized and both 
genetic and molecular reasons behind the impaired lysosomal function are 
known, the cause of the symptoms is not clear. Lysosomal dysfunction and 
accumulation of glycopeptides explain the symptoms and the decrease in 
mental and physical health, but molecular mechanisms and the causes behind 
the progressive clinical picture remain unresolved. Because of the unknown 
aspects of the disease and versatile symptoms, it can be hypothesized that a 
significant portion of the cases remains underdiagnosed. This could be the 
case especially in countries where the disease heritage does not include 
lysosomal storage diseases, contrary to Finland, where the clinical knowledge 
of LSDs is relatively good based on the homogenous population and the 
disease heritage including LSDs. 
  
2.3.2 Treatment options available  
  
Currently, there are no medicines available for the treatment of AGU, although 
bone marrow transplantation (BMT) and a small molecule chaperone therapy 
have been studied in human patients. In a follow-up study by Arvio et al in 
2001, seven AGU patients between the ages of 1-10 received a BMT. After a 
follow-up period of one to seven years, two of the seven patients who were 
followed for the longest period were more severely mentally retarded than the 
AGU patient control group. The other five transplantations were successful, 
but the follow-up period was inadequate to prove effectiveness of the 
treatment. The research group concluded that BMT is not enough to restore 
the AGA function in patients with AGU or that the BMT should be done early 
in infantry.   
Recently, a set of small molecules have been studied for use in 
pharmacological chaperone therapy for AGU. (Banning et al, 2016) The group 
studied different mutations and their response to the molecules in an in vitro 
setting using primary cells obtained from patients. The molecules studied were 
betaine, glycine and aspartate, which were chosen by their potential to use as 
pharmacological chaperones in stabilizing the AGA enzyme structure. All three 
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compounds were found to increase AGA activity within the two disease-
causing mutations studied, AGUFIN and Thr122Lys, both of which show 
inadequate AGA activity. However, when a clinical relevancy study for all three 
compounds was conducted with purified recombinant AGA, in order to see if 
the molecules inactivate the enzyme itself in higher concentrations, only 
betaine proved to not affect the enzyme function itself in bigger concentrations. 
Thus, out of these three compounds, betaine was chosen to advance to a 
clinical study for patients with the researched mutations. This clinical study is 
currently ongoing. In addition, betaine is approved for clinical treatment of 
homocystinuria by both EMA and FDA under the trade name Cystadane. 
(European Medicines Agency, Cystadane: EPAR; clinicaltrials.gov: 
NCT01838941)  
In addition to these abovementioned small molecules studied, another 
molecule progressed to further studies. Amlexanox proved to have potential in 
an in vitro setting in stabilizing the enzyme structure in disease cases resulting 
from a nonsense mutation. (Banning et al, 2018) This molecule was shown to 
increase AGA mRNA levels in patient fibroblasts with Ser72Pro and Trp168X 
mutations. Patients with nonsense mutations like this exhibit less severe 
disease pathology and they have more residual enzyme activity than patients 
with the AGUFIN mutations and thus, this treatment option cannot be used for 
the more severe point mutations.   
From a drug developmental perspective, a translational disease model must 
be available. For AGU, two different types of mice models have been 
developed, both of which are knockout models (Kaartinen et al, 1996; Jalanko 
et al, 1998; Tenhunen et al, 1998). The first type has the entire AGA gene 
knocked out (Aga (-/-)), (Kaartinen et al, 1996; Jalanko et al, 1998) whereas the 
second model type mimics the AGUFIN major mutation and thus only short 
sections of the gene are knocked out (Tenhunen et al, 1998). It must be kept 
in mind that to be properly translational, a patient mutation is always a closer 
representation of the real disease compared with a total knock-out model. This 
might, however, mean that symptoms do not manifest in mice as they are 
represented in the human patients, which presents challenges to the in vivo 
research of the disease and the translatability of the model. Luckily, this is not 
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the case with either of the AGU mice models. The in vivo models for AGU are 
highly translational, exhibiting same clinical manifestations and progressive 
nature of the symptoms similarly to the progression seen in patients. 
Histologically, the Aga-/- mice show enlarged lysosomes in both CNS and 
peripheral tissues, which resembles the findings in patient tissues. (Kaartinen 
et al, 1998) In addition to the histological findings, the Aga-/- mice show 
significantly affected gait, e.g. dragging of their hind legs. It has also been 
reported that the mice have deprived coordination and balance correlating with 
the motor function impairment of AGU patients and the mice only live about 
half as long as the healthy mice. (Gonzalez-Gomez et al, 1998)  
Thus, both in vitro and in vivo models have been established for AGU, but no 
breakthrough for therapy applications has been developed. According to 
Mononen et al (1995) and Dunder et al (2000), when AGA is introduced in vitro 
to a cell culture from AGU patient, the enzyme is endocytosed and function of 
aspartylglucosamine is restored. However, in an in vivo model, the enzyme 
replacement therapy restores the enzyme function in other tissues but not the 
brain, where GlcNAc-Asn accumulation causes the most serious 
developmental defects. The difficulties for the enzyme to cross into the brain 
is due to the protective nature of BBB, which inhibits the access of AGA to the 
CNS. Regardless of both in vitro and in vivo models and studies of AGU, no 
treatment benefiting the patients has been developed.   
  
2.4 Summary  
  
Clearly, there is a vast unmet medical need in terms of treatment options for 
lysosomal storage diseases. This applies to all LSDs, including AGU, one of 
the severe Finnish heritage diseases and the focus of this study. Since the 
disease is rare, about 1:18 000 live births affected in Finland, and no cure is 
available, it can be hypothesized that the disease is also underdiagnosed at 
least on global scale. AGU is diagnosed from urine in terms of secreted 
GlcNAc-Asn, and if a treatment was available, diagnosing yet asymptomatic 
newborns would be reasonable and would possibly increase the disease 
prevalence. In addition to the clear unmet medical need, the underlying 
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pathological mechanisms causing the symptoms and the progressive nature 
of the disease are not fully understood, and a lot remains to be discovered. 
Patients affected show decline both physically and mentally, and what causes 
this progressive nature of the symptoms in both periphery and CNS remains 
to be discovered. The accumulation of a metabolic product due to 
malfunctioning enzyme is the primary disease-causing process, but the 
molecular mechanisms following lysosomal accumulation are not completely 
known.  
In order to be able to treat patients suffering from lysosomal storage diseases, 
the disease pathology needs to be understood and the differences between 
healthy and pathological conditions characterized. Characterization of the 
differences is the key concept in this thesis and aim of the research. By utilizing 
various biomedical research methods, the aim was to unravel the cellular and 
molecular differences within the cells underlying the pathological state and the 
symptoms manifesting in the AGU patients. The research focused on the 
enzymatic differences within AGU and healthy cells and on establishing a 
reliable model for lysosomal storage diseases. This work enables the future 
research in Orion focusing on methods aiming to restore the enzymatic 
function or reducing the accumulation of substrates with other means within 
the selected LSDs.   
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3. Results   
  
3.1 Cell maintenance  
  
Both lymphocytes and fibroblasts from healthy and AGU-patient donors were 
maintained throughout the study. Lymphocyte growth media supported the 
growth of lymphocytes and no differences in growth pattern were observed 
between the healthy and AGU patient cell lines. Lymphocyte cell cultures were 
passaged as the supplier instructed.   
Fibroblasts exhibited distinct differences both morphologically and in their 
growth patterns. The growth was poor with especially the AGU fibroblasts, and 
thus, the growth media for AGU fibroblasts was supplemented with 20% fetal 
bovine serum to facilitate the growth. Despite the modifications, growth rate of 
the AGU vs healthy fibroblasts continued to differ along the passages. The 
healthy control fibroblasts exhibited a steady growth curve with also larger 
passages, but around passage 20, the growth rate of AGU fibroblasts started 
to decline. Morphologically, the AGU fibroblasts did not form a uniform, 
systematically growing cell layer as did the healthy control fibroblasts. (Figure 
3) AGU fibroblast vessels contained significantly more cell debris floating in 
the medium and the cells had debris attached to the cell surface as well. 
Individual AGU cells were not morphologically comparable with the healthy 
fibroblasts. Some of the cells showed a round phenotype with a tumor-like 
appearance, which was not seen in the healthy cell culture. Cell culture cross-
contamination with a cancerous cell line, however, is not possible.   
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When passaging the cells, the healthy controls attached to the bottom of the 
growth vessel significantly better than the AGU cells and thus, there was less 
cell death occurring within the control flasks than with the AGU fibroblasts.   
Detaching fibroblasts was optimized with 0.04%, 0.08%, 0.16% and 0.25% 
trypsin in 0.53 mM EDTA in HBSS, and 0.25% trypsin in DPBS. The cells 
detached adequately with only the highest trypsin concentration. 
Approximately five passages were grown parallel to investigate the possible 
morphological changes caused by the higher trypsin concentration, but no 
changes were observed and thus the detaching protocol was modified to use 
one DPBS wash followed by 0.25% trypsin in DPBS until the cells detach to 
ensure throughout detachment and proper subculture progenitors.  
AGU fibroblasts p15 Healthy fibroblasts p10 
4X 
10X 
Figure 3. Microscopic images of both AGU and healthy fibroblasts. 7 
days after last passage to same confluence with 4X and 10X 
magnifications. AGU fibroblasts present a less organized cell layer and a 
slower growth rate when compared to the healthy fibroblasts, which grow in 
an organized cell layer. Scale bar 100 µm in 10X and 250 µm in 4X images. 
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3.2 Enzyme activity measurements   
 
Enzyme activity was measured with a fluorescent ligand, Asp-AMC, emitting a 
signal when cleaved by the AGA enzyme to free asparagine and fluorescent 
AMC group. The activity of AGA was stabile in both healthy and patient cell 
lysates throughout the reaction. Healthy cells exhibit an activity sufficient to 
break down the metabolic product causing AGU, but in AGU cells, the enzyme 
activity is not enough to metabolize GlcNAc-Asn. Although the enzyme activity 
in AGU cells is not completely absent when comparing with a control sample 
without any cell lysate, it is approximately one tenth of the activity in the healthy 
samples and thus only emits a fracture of the signal that of healthy cell lysates. 
This can clearly be seen in the 6-hour measurement, where the signal emitted 
from the fluorescent substrate cleavage is constant (Figure 4).  
The enzyme activity was also measured with 24-hour end-point measurement. 
This measurement confirmed that the signal is steady even for longer periods 
of time, which suggests that this study setting is suitable for modeling the 
biological state of the cell lines and their differences. In figure 5, a graph from 
Figure 4. The enzyme activity of AGA measured every 2 minutes for 6 
hours. The activity in healthy cells is stable and about 8-fold compared with 
AGU lymphocytes. Mean + SD of each time point shown. 
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the end-point measurement shows a significantly higher (p <0.0001) enzyme 
activity in healthy cells compared with the AGU cells.  
  
The Km value for AGA enzyme within the healthy lymphocyte lysate was 
determined from a standard curve with Michaelis-Menten equation (Figure 6). 
The Km value for the healthy lymphocyte AGA enzyme was determined to be 
17.01. This indicates that the concentration at which half of the enzyme is 
bound with substrate is 17.01 µM. Previously, Km for wild type AGA has been 
reported to be 93 μM (Mononen et al, 1993), 2500 µM (Tikkanen et al, 1996) 
and 444 µM (Saarela et al, 2004) depending on the protocol used.  
 
Figure 5. Aga activity measurement at 0 h and 24 h from both AGU and 
healthy cell lysate. AGA activity can be seen in both, but in healthy cells 
AGA activity is significantly higher (p <0.0001) after 24 h compared with the 
AGU cells, in which the activity is five-fold smaller. 
*** 
*** 
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3.3 GlcNAc-Asn measurement  
  
The amount of AGA substrate within the cell was measured with mass 
spectrometry analysis. The analyses were done from the GlcNAc-Asn 
amounts from lymphocyte lysates prepared from healthy and AGU cells. In 
figure 7, the mass spectrometry results show a significantly higher 
concentration (p<0.0001), approximately 20-fold, of GlcNAc-Asn in the AGU 
lymphocytes compared with the healthy cell lysate. 
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Figure 6. Km value of AGA in healthy lymphocytes. Calculated 
with the Michaelis-Menten equation. 
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Recombinant enzyme restores the enzyme activity and thus decreases the 
amount of the enzyme substrate accumulated within the cells. This can be 
seen from the figure 8 showing the amount of the substrate, GlcNAc-Asn, 
within AGA treated AGU and healthy control cells, and untreated AGU cells. 
The cells were grown for four days under normal culturing conditions, and in 
addition, 1 µg/ml of recombinant AGA was added to the medium in one flask 
of the AGU cells, approximately 200 000 cells/ml. After four days, the cells 
were lysed and  the amount of the substrate in the cells was measured with 
mass spectrometry analysis. The AGU cells grown with 
aspartylglucosaminidase had a significantly decreased (p=0.0002) amount of 
GlcNAc-Asn compared with the untreated cell line and thus, had an increased 
enzyme activity. As seen from the figure 8, the level of GlcNAc-Asn is only 
slightly larger in (3-fold) AGA supplied AGU lymphocytes than the amount of 
the substrate in healthy cells, compared with the 20-fold difference between 
healthy and untreated AGU cells. This suggests that the active enzyme is able 
to cross the cell membrane and enter the lysosomes, and that the enzyme 
Figure 7. Aspartylglucosamine concentration in AGU and healthy 
lymphocytes. The concentration in AGU lymphocytes is significantly bigger 
(p<0.0001) than in healthy lymphocytes, in which functioning AGA enzyme 
cleaves GlcNAc-Asn inhibiting the lysosomal accumulation. Mean + SD 
shown. 
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activity is preserved for at least four days in culturing conditions that mimic the 
physiological state.   
 
 
  
Figure 8. GlcNAc-Asn amount in healthy, AGU and AGU treated with 
recombinant AGA lymphocyte lysates. Substrate amount decreased 
significantly (p=0.0002), about six-fold, when recombinant AGA was added to 
cell culture medium. Mean + SD shown. 
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3.4 Immunostaining  
  
3.4.1 LysoTracker DeepRed timepoint study  
  
LysoTracker timepoint imaging with live cells was conducted for 18 hours, with 
one image every 20 minutes. From this timepoint measurement study (Figure 
9), LysoTracker staining and starvation time were further optimized, and the 
optimal imaging timepoint was defined to be up to eight hours, after which the 
differences begin to fade. From these results the differences between the AGU 
cells and healthy controls were evident. AGU cells had significantly higher spot 
intensity in analysis compared with the healthy cells, where signal was 
relatively small throughout the experiment. This suggests, that the AGU 
fibroblasts under normal conditions had either bigger lysosomes due to the 
accumulated GlcNAc-Asn or bigger number of lysosomes giving a higher 
relative signal per well compared with the healthy fibroblasts.  
Comparing the signal curves on figure 9 it can be seen that starvation of the 
healthy cells increased the LysoTracker signal to the same level as the AGU 
cells in normal medium. A significant increase can be seen in both healthy and 
AGU cells between starved and normal conditions. Starved AGU signal is 
clearly higher than the other signals, and healthy control cells without 
starvation emit the lowest signal. The signals remain relatively stable up until 
approximately time point 8 h, after which the signal starts to decrease in cells 
with highest signal and increase in cells with the lowest signal thus making the 
relative differences smaller. Thus, starvation increased LysoTracker signal in 
both cell types. This would imply that the number of lysosomes increases in 
response to nutrient deprivation and lysosome biogenesis machinery is 
activated, and this response seems to function adequately in both cell lines. In 
conclusion, the AGU cells seem not to be impaired in their ability to employ the 
lysosomal biogenesis process and that the baseline of lysosomal signal is 
elevated even under non-starved conditions in AGU cells compared with the 
healthy cells.   
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3.4.2 Co-location of LAMP-1 and LysoTracker Deep Red  
  
To compare the LAMP-1 antibody and LysoTracker on their efficiency to 
recognize lysosomes, a co-location study was conducted. Fibroblasts were 
incubated with LysoTracker Deep Red before fixation and stained with 
antiLAMP1 to study the colocalization of LAMP1 antibody and lysosomes. 
LAMP-1 signal overlapped with 20-30% of the LysoTracker signal, whereas 
LysoTracker signal overlapped with over 50% of the LAMP-1 signal (Figure 
10). Thus, the anti-LAMP-1 antibody is not specific enough to be used in further 
studies concentrating on intracellular compartmentalization of lysosomes and 
LysoTracker is to be used in future experiments to obtain as reliable results as 
possible.   
Figure 9. Time point measurement of LysoTracker signal with AGU 
and healthy fibroblasts under starved and normal conditions. 
According to the results, the optimal time point for imaging starvation 
response with LysoTracker is at around 6 h after the start of starvation. 
The y-axis represents relative units. 
Time (h) 
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3.4.3 Starvation  
  
Starvation experiments were conducted with plated fibroblasts from both 
healthy and AGU individuals. Starvation was induced by depleting the growth 
medium from FBS. Based on the time point study with LysoTracker DeepRed, 
Figure 10. Co-localization study of LAMP-1 and LysoTracker. LAMP-1 
in green and LysoTracker in red. LysoTracker stains lysosomes more 
specifically, 50% of LysoTracker overlaps with LAMP-1 staining. LAMP-1 
staining has more unspecific staining, which looks blurry. 20-30% of LAMP-
1 staining overlaps with LysoTracker. 50 µm scale bar, orange 
staining=phalloidin, blue staining=DAPI. 
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starvation was decided to be studied for 6 h. For the last 30 minutes of the 
starvation, LysoTracker DeepRed was added to the wells. After starvation, the 
cells were washed, fixed, stained with phalloidin and DAPI and imaged. The 
images were analyzed for the localization of the stained lysosomes, by their 
distance from the nucleus. This was done utilizing the software in the imaging 
system, which analyzed the LysoTracker DeepRed staining according to the 
distance from the nucleus. The cells were divided into perinuclear and 
peripheral areas, which determined the localization of the lysosomes. These 
results were exported to GraphPad Prism for further statistical analysis.  
 
By analyzing these photos, the differences between the starved and normal 
conditions were clearly visible (Figure 11). When starved, the cells relocate 
the lysosomes to perinuclear areas, which is seen from the change in the 
intensity of the LysoTracker DeepRed signal within perinuclear and peripheral 
areas in the cells. Comparing the response to starvation between healthy and 
AGU patient fibroblasts, the lysosome relocation response seems to be similar. 
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Figure 11. Lysosome positioning in response to 6 h starvation in AGU 
and healthy fibroblasts. The perinuclear lysosomal signal increases 
significantly in response to starvation in both cell populations (p<0.0001). 
Perinuclear increase after starvation is more significant in both cell lines 
when comparing with the non-starved condition. In addition, the peripheral 
signal in both healthy and AGU (p=0.0135 and p=0.0337, respectively) cells 
increased significantly in response to starvation. Mean + SD shown. 
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In both cell lines, starvation mobilizes the lysosomes towards the perinuclear 
area, which leads to an increase in LysoTracker DeepRed signal closer to the 
nucleus. 
 
 In periphery of the cells, the signal is not significantly altered in either of the 
cell lines, which would imply that the increment of signal perinuclearly is partly 
due to lysosomal biogenesis. In both cell lines, the perinuclear signal increased 
statistically significantly in response to starvation (p<0.0001 in both healthy 
and AGU cells). This suggests that lysosomal biogenesis is increased in both 
cell lines when the cells are deprived of nutrients. In addition, the peripheral 
signal in both healthy and AGU cells increased statistically significantly under 
starvation (p=0.0135 and p=0.0337, respectively). This increase was, 
however, notably smaller than perinuclear increase.  
 
Another 96-well plate of healthy and AGU fibroblasts was stained similarly to 
the previous starvation study. The cells were imaged after 6-hour starvation, 
fixation and staining. The AGU fibroblasts exhibited polyploidy, (Figure 12) 
which was not seen in the healthy fibroblasts nor in either cell line in lower 
passages. Polyploidy was observed within cells after 30th passage, but only in 
AGU fibroblasts.   
In addition, healthy and AGU fibroblasts differed in an increase in cell size in 
AGU cells compared with the healthy cells. This can also be seen from figure 
12, where healthy fibroblasts exhibit a homogenous cell population in terms of 
size and organization, but the AGU cells, in addition to polynucleated, also 
significantly enlarged.  
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Healthy fibroblasts p35 AGU fibroblasts p32 
Figure 12. Different phenotype in AGU cells with higher passage. High 
passage AGU fibroblasts exhibit multinucleated cells (arrows) and 
enlargened cytoplasm, which is not seen in healthy fibroblasts even in high 
passages. Nucleus stained with DAPI (blue) and cytoskeleton with 
phalloidin (orange). Scale bar 50 µm. 
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3.4.4 TFEB staining  
  
Both AGU and healthy fibroblasts were immunostained with anti-TFEB 
antibody to study the localization of TFEB in response to starvation. (Figure 
13) The cells were starved for two hours in growth medium depleted of both 
serum and non-essential amino acids. After starvation, the cells were fixed and 
stained with anti-TFEB, phalloidin and DAPI. Nuclear TFEB signal was present 
in both starved and non-starved AGU cells, whereas only the starved healthy 
cells exhibited nuclear localization of TFEB. This suggests that there are 
AGU Healthy 
Normal 
conditions 
Starved 
conditions 
Figure 13. TFEB localization under normal and starved 
conditions. In AGU fibroblasts, TFEB is in nucleus in both starved 
and non-starved conditions, whereas in healthy cells the change 
in the culturing conditions and following relocation into the nucleus 
in response to starvation is more evident.  
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differences in TFEB phosphorylation regulated by mTOR between the AGU 
and healthy cells, which is seen in constant activation of TFEB. Under normal 
conditions, as in healthy cells, TFEB remains in its phosphorylated inactive 
state within the cytosol and is only activated by cellular stress.  
3.5 Western Blotting  
  
The expression and amount of the enzyme AGA within the AGU and control 
cells was studied with Western Blot. Three different antibodies were tested, 
and vinculin was used as the loading control. All three antibodies recognized 
the protein and right size bands were formed, but after optimization and based 
on the intensity of the signal, abcam anti-AGA was chosen for further 
experiments. 
 
 In figure 14, the differences between the intensity of the signal from the three 
antibodies can be seen. Only Abcam antibody recognized the AGA enzyme 
100 kDa 
150 kDa 
75 kDa 
50 kDa 
37 kDa 
ab1 ab2 ab3 
H    A H    A H    A 
Figure 14. Antibody test with three different anti-AGA (42 kDa) 
antibodies. Vinculin (124 kDa) used as a loading control. Only ab3 
recognized AGA with 1:1000. A third band is seen at ab3 due to 
spillage from AGU sample and a bigger, unspecific band at >150 
kDa. H=Healthy, A=AGU, ab1=Novus Biologicals (NBP1-79881) 
ab2= Novus Biologicals (NBP1-88866), ab3= Abcam (ab231021). 
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peptide with the 1:1000 dilution, which was recommended by all three antibody 
suppliers. The recognized AGA bands can be seen at 42 kDa in figure 14. In 
addition, a third band can be seen in addition to the healthy and AGU cell 
lysate due to spillage from the well of the AGU lysate. A bigger band at over 
150 kDa can be seen, and this is due to unspecific binding of the anti-vinculin 
antibody. Based on this result, Abcam antibody was chosen to future Western 
Blot analyses.  
 
After choosing the antibody, further Western Blotting experiments were 
conducted with different amounts of protein: 50 µg/ml, 75 µg/ml and 100 µg/ml. 
We wanted to compare the differences in the enzyme levels in healthy and 
AGU lymphocyte lysates with the Abcam antibody, which proved to give the 
most intense bands. In figure 15, the differences in the intensity of the bands 
between cell lysate from healthy and AGU lymphocytes can clearly be seen. 
The healthy lymphocytes exhibit bands of smaller intensity when comparing to 
the AGU lymphocytes, with all three different loaded protein amounts tested. 
The biggest intensity difference is seen with a band approximately 42 kDa in 
size, where AGU lymphocytes show a much clearer band compared with the 
healthy cell lysate. The most intense band is the size of the uncleaved enzyme, 
which is given by the antibody manufacturer as the recognized size. The 
intensity of the AGU cell lysate band is 2.26 times higher than the intensity of 
the band for healthy cell lysate when normalized with the loading control 
intensity, thus, there is 2.26 times more uncleaved AGA enzyme within the 
AGU cells compared with the healthy cells.   
  
This suggests that the enzyme production itself is not impaired within the AGU 
lymphocytes, but the cleavage of the enzyme into its two subunits does not 
occur as in the healthy state. Thus, the AGUFIN major mutation that is present 
in the AGU lymphocytes prevents the cleavage and formation of the active 
AGA enzyme, but not the transcription or translation of the peptide chain itself.  
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50 µg 
protein 
75 µg 
protein 
100 µg 
protein 
100 kDa 
150 kDa 
75 kDa 
50 kDa 
37 kDa 
H     A H      A H      A 
Figure 15. A dilution series of loaded cell lysate. A dilution series with 
50, 75 and 100 µg of loaded protein show a stable 2.26 times higher AGA 
precursor amount in AGU lymphocyte lysate compared with the healthy 
cells (marked with red) when normalized with vinculin band intensity. 
Vinculin (124 kDa) was used as loading control. H=Healthy, A=AGU. 
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4. Discussion  
  
4.1 Cell maintenance  
  
Fibroblasts from an AGU patient and an age- and gender-matched control 
showed very different characteristics both morphologically and growth-wise. 
Since the growth pace for the AGU fibroblasts was very slow, the serum 
concentration was altered by increasing the FBS concentration from 15% to 
20% as the cell supplier had suggested in their instructions. Despite these 
alterations, the AGU and healthy cells continued to differ in their growth rates. 
Interestingly, when comparing the different cell types for this phenomenon, the 
lymphocytes behaved differently. No differences in the growth rate were seen 
between the AGU patient lymphocytes and their age- and gender-matched 
healthy controls. Both cell lines grew consistently even when growing 
passages and the sub-culturing rate was the same for both AGU and healthy 
cells. Morphologically, the lymphocytes showed no differences when 
observing them under a microscope. No previous studies could be found which 
would have reported the morphological characteristics of these primary cell 
types, even if multiple studies have been conducted with these cell lines.  
(Fisher & Aronson, 1991; Mononen et al, 1991; Greco et al, 2003; Sarkar et al, 
2018)  
These findings support the decision to have at least two different cell types 
grown and investigated parallel to each other in case of cell-type specific 
problems occur. Since the four cell lines were obtained from four different 
individuals, the two different AGU cells’ growth rate compared with their 
healthy controls might be due to the differences in the individuals the cells 
originate.   
When the cell culture continued, the AGU fibroblasts started to show distinct 
morphological differences compared to the healthy fibroblasts. Observing the 
cell cultures under a microscope, the cells showed a significantly different 
phenotype. AGU patient cells had cell debris and significant number of dead 
cells in their growth medium after each subculture, compared with the healthy 
44 
 
fibroblasts. These differences might be caused by the poor attachment of AGU 
cells to the culturing vessel, which causes the cells to lose the natural growth 
condition and to undergo cell death. The debris might also originate from the 
unattached dead cells. Poor attachment might also be the cause for the poor 
growth rate, when a significant proportion of the sub-cultured cells does not 
survive. Although fibroblasts growing in situ are a very quickly renewable cell 
type, in primary cell culture, the poor attachment may be the underlying cause 
for poor growth. The differences are contrary to the findings of Näntö-Salonen 
and Penttinen (1982). They studied primary fibroblast cultures from skin 
biopsies of AGU patients and a healthy age- and gender matched controls 
under similar growth conditions and passages as the cells grown in this study. 
The group analyzed the cells for their growth rate and saw no differences 
between the AGU and healthy controls. Although same growth rates, Näntö-
Salonen and Penttinen found that the synthesis of collagenous proteins was 
decreased in AGU cells compared with the healthy controls. Skin-affecting 
symptoms have also been reported in AGU patients by Arvio et al in 1999.  
  
4.2 Enzyme activity measurement  
  
The AGA enzyme activity measurements from the healthy and AGU cell 
lysates show a stabile enzyme activity in both cell lines, although in AGU cells 
the enzyme activity is below the sufficient activity needed for the cells to 
function adequately, being about 1/10 of the activity of the healthy cells. These 
baselines measured for both cell lines can now be used in future experiments 
as reference when comparing the enzyme levels between, for example, 
different treatment options.   
Enzyme activity measurement for the commercially available recombinant 
enzyme showed that 1 µg/ml of enzyme exhibited enzyme activity by cleaving 
the substrate accumulated within the cells. This suggests, that in theory, the 
recombinant enzyme could be used to replace the inactive enzyme in AGU 
cells and that, with the right concentrations, the enzyme activity could be 
increased to sufficient levels also in the AGU cells. This was proven to work in 
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the lymphocyte culture: adding the recombinant enzyme to the culturing media 
increased the enzyme activity within the AGU cells by being able to decrease 
the amount of the enzyme substrate accumulation within the cells. Adding 
recombinant enzyme to the cell culturing media proved that the enzyme is 
endocytosed at an appropriate rate and that the enzyme activity remains high 
enough for the breakdown of the metabolic product for at least four days. The 
endocytosis happens probably via the MPRs located on the cell surface, and 
this allows the transportation of the enzyme to the lysosomes. Since the 
enzyme is a lysosomal enzyme, it requires an acidic environment in order to 
break down the substrates. Since the functionality was detected, it can be 
concluded that the enzyme is indeed transported to the lysosomes and 
remains intact for at least the now studied four days. In addition to this, it can 
be concluded that the acidic environment is preserved in the lysosomes also 
in the AGU states, based on the enzyme function. In addition, the LysoTracker 
DeepRed staining supported this by recognizing specifically the acidic 
environment of the lysosomes and endosomes. Thus, at least in AGU, the 
pathophysiology is not directly affecting the acidification of the lysosomes. This 
acidification process occurs through the V-ATPase located on the lysosomal 
membrane (Ohkuma et al, 1982), as discussed before. In addition to the V-
ATPase, the lysosomal membrane enables the normal function by protecting 
the acidic environment from getting into contact with the cytosolic 
compartments (Alberts et al, 2015). In consideration with the results obtained, 
it can be stated that the acidification process and the protective membrane are 
functional enough to not be the underlying cause for the pathology in the AGU 
cells. 
Of course, there are several different factors that need to be considered before 
these theories can fully be implemented to the pathophysiology of the 
lysosomal storage diseases. For example, regarding the endocytosis rate for 
the recombinant enzyme, there are multiple different factors that needs to be 
taken into account. Further studies are needed to investigate further e.g. the 
presence and exploitation of MPRs in physiological conditions and the level of 
the enzyme activity in cell culture conditions. However, an increase in enzyme 
function and decrease in the quantity of accumulated protein of this magnitude 
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with only 1 µg/ml of protein suggests, that treatment with a corresponding 
amount in humans, 1 mg/kg, could be possible in theory.   
  
4.3 LysoTracker time point analysis  
  
LysoTracker time point study with healthy fibroblasts, AGU fibroblasts, starved 
healthy fibroblasts and starved AGU fibroblasts was conducted over an 18- 
hour period and the cells were imaged every 20 minutes. The differences 
between the groups are most evident from 2 hours up to 8 hours. This suggests 
that after the depletion of serum from the growth media, it takes at least two 
hours for the autophagic machinery to start the degradation process when 
deprived of nutrients. Since the autophagy is thought to continue for longer 
than three hours from its imageable peak, the decrease in signal intensity 
might be caused by the fading of the fluorescent label of the LysoTracker due 
to tens of exposures to light after numerous images and the initial dilution 
protocol of the LysoTracker.   
The decrease of the fluorescent signal may also be due to the alkalizing effect 
of the LysoTracker, which causes the signal to weaken since the probe is 
activated by the acidic environment of the organelles. Indeed, this must be 
considered when interpreting the results, but for future experiments, this 
should not play a significant role since the cells are not to be imaged for 
extensive periods.   
Based on these findings, further optimization for starvation was performed after 
the time series study. In future experiments, the LysoTracker label was 
introduced to cells after 5.5 h of starvation for the imaging to take place at 6 
hours from the nutrient deprivation initiation. The starvation conditions were 
also altered by fully depleting the FBS from the growth medium of the cells in 
contrast to the timepoint study, where growth medium containing 5% FBS was 
used. In future experiments, the LysoTracker is a useful tool to image the 
lysosome activity within the cells. Although LysoTracker is not lysosome 
specific as it stains according to the low pH of the vesicles and thus may 
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recognize also late endosomes, it is still a convenient probe for lysosomal 
studies.   
  
4.4 Starvation and immunofluorescent staining 
  
Several 96-well plates were studied combining the starvation, LysoTracker 
labelling and antibody staining for fixated cells. The primary aim was to study 
the distribution of the lysosomes in starved cells compared with the healthy 
nonstarved fibroblasts, and to compare these with the AGU fibroblasts under 
starved and normal conditions. LAMP-1 recognizing antibody was used to 
compare the lysosome staining specificity between LAMP-1 antibody and 
LysoTracker.   
In a study conducted by Banning et al in 2016, patient fibroblasts from the 
same AGU-patient as in this study were stained with LAMP-1 and LysoTracker 
together with a control fibroblast from a different source. These results are 
conflicting with our immunostaining results in terms of the lysosome amounts 
in the patient and control fibroblasts. In the study by Banning et al, the LAMP-
1 and LysoTracker stained organelles were significantly more numerous than 
in the healthy fibroblasts, and this difference was not as profound in our study. 
These differences may be due to the differences in the healthy control 
fibroblasts, since they were obtained from a different source. The stainings 
were probably also done with different passages, although the passages of 
used cells were not revealed in the Banning et al study. The cells were cultured 
under different culturing conditions, which might also play a role, although 
since both the healthy and AGU cells were in same conditions in both studies, 
this should not affect the differences between the specific cell lines. In future 
studies, this staining should be repeated in mimicked conditions from Banning 
et al study, after which further conclusions from the reasons behind observed 
differences between the studies could be drawn.   
The small co-localization percentages were probably due to the different 
properties of the probes. LAMP-1 is a surface protein expressed on the lipid 
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layer of lysosomes and is also found on the lipid layer of late endosomes. In 
addition to this, it must be considered that antibodies behave differently than a 
chemical probe. There is always a possibility of unspecific binding, although 
commercially available antibodies should be relatively specific. Indeed, these 
factors must be considered when analyzing the results of the staining. On the 
other hand, LysoTracker stains according to the acidic environment within the 
lumen of the cellular organelles, and lysosomes are not the only organelles 
exhibiting a decreased pH. In addition to lysosomes, also late endosomes 
have an acidic lumen and thus, none of these methods can fully differentiate 
the lysosomes from their predecessors.   
Based on the comparison of the antibody and LysoTracker colocalization, 
LysoTracker was chosen for future experiments due to the higher percentage 
of overlapping with LAMP-1 than what LAMP-1 overlapped with LysoTracker. 
In addition, LysoTracker is easily and reliably repeatable and offers the 
possibility to use more immunofluorescent probes due to its infrared 
wavelength.   
The second staining of fibroblasts in a similar setup as the LAMP-1 and  
LysoTracker comparison yielded different results. The cells were starved, 
incubated with LysoTracker and stained with phalloidin and DAPI, in order to 
analyze the distribution of the lysosomes. Due to the significantly different 
phenotypes of the already older cells between healthy and AGU, no analysis 
could be conducted since the validity of the results could not be guaranteed. 
The AGU fibroblasts were notably bigger in size, and many of the cells had 
multiple nuclei or a nucleus that was scattered, not uniform, and did not exhibit 
a round shape as like healthy cells. In addition to this finding, the healthy cells 
grew in an organized manner, and the AGU cells were scattered disorderly as 
seen in figure 3, in chapter 3.1 Cell Maintenance and figure 12 in chapter 
3.4.3 Starvation.   
The abnormality of nuclei in AGU fibroblasts is possibly due to either cell fusion 
or an aborted mitosis, where nucleus is divided but the mitosis process is not 
advanced further to full cell mitosis. In macrophages, multinucleated cells can 
form also via phagocytosis. (Hornik et al, 2014) In a study conducted by Sukita 
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et al in 2019 multinucleated cells were produced by incomplete mitosis. 
Xenopus tadpole epithelium tissue-derived cell line (XTC-YF) was used to 
investigate conditions under which multinucleated cells form. The group 
altered the surface hydrophilicity of the cell culture surfaces, which makes the 
results not completely applicable with our results. Since the phenomenon was 
seen after immunofluorescent staining, it can only be stated that fibroblasts 
exhibited polyploidy due to no staining of lymphocytes.  
Since this phenomenon is not detected in the healthy fibroblasts, it can be 
hypothesized that the impaired lysosomal function is at least partially causing 
the atypical nuclei. Arvio et al (1999) reported facial angiofibromas and 
erythema and seborrhoeic skin to be more frequent in AGU patients than in 
general population. However, in vitro growth conditions are incompatible with 
the normal multicellular tissue conditions.  The unorganization of the AGU 
fibroblast cell culture might be the in vitro equivalent to the skin symptoms 
reported by Arvio et al in 1999.   
In 2018, Samarani et al reported of cell cycle arrest coupled with abnormal 
lysosomal function. The group induced LSD-mimicking conditions by loading 
lysosomes with sucrose, commonly used to impair lysosomal function and 
study the consequences. Decrease in proliferation rate, increase in apoptotic 
cells and downregulation of cell cycle regulating genes was observed. 
However, the findings by Samarani et al cannot directly explain the atypical 
nuclei discovered in the AGU patient cells when staining with DAPI. Cell 
growth arrest may explain the splitted nucleus, if cell undergoes mitosis up 
until the splitting of cytoplasm, which is not completed because of 
downregulated genes regulating the cell cycle. This remains to be studied in 
the future.  
A second starvation experiment was conducted with fibroblasts, similar to the 
previous experiment with LysoTracker DeepRed and LAMP-1 staining, and 
with cells with smaller passage. The cells were depleted of FBS for 16 hours, 
after which they were stained with LysoTracker, phalloidin and DAPI. The cells 
were imaged, and the images were analyzed by the distribution of lysosomes 
peripherally or perinuclearly. There was a significant increase in the 
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perinuclear intensity of the LysoTracker when the cells were starved, 
compared with the non-starving conditions. This can be explained by the 
autophagic machinery reacting to the absence of nutrients. The cellular stress 
caused by the deprivation of nutrients triggers the relocation of TFEB into the 
nucleus, which results in transcriptional activation of genes regulating 
autophagy and lysosomal biogenesis. This lysosomal biogenesis can be seen 
from the images obtained after the starvation experiment, in an increased 
signal within the perinuclear area (Figure 11). In line with this result is the 
increase in nuclear TFEB signal in immunostaining. TFEB is the transcriptional 
activator of lysosomal proteins required for lysosome biogenesis in response 
to nutrient deprivation. This biogenesis starts when TFEB is activated and 
relocates into nucleus, as seen from the immunostaining (Figure 13) images. 
In AGU cells in contrast, TFEB is located in the nucleus even under non-
starved conditions. In 2009, Sardiello et al demonstrated the nuclear relocation 
of TFEB in response to lysosomal stress in HeLa cells after sucrose 
supplementation, which is commonly used to mimic lysosomal stress and 
lysosomal storage diseases. Since AGU cells exhibit TFEB localization in 
nucleus under both starved and non-starved conditions, it can be thought that 
TFEB signaling route is not impaired per se.  However, regardless of TFEB 
localization within the nucleus the effect of its active state is not seen as an 
increase in lysosomes in AGU cells. When reflecting on the non-starved 
conditions in lysosome localization study and comparing with healthy cells the 
lysosomes of AGU cells are not closer to the nucleus nor is the perinuclear 
lysosome amount increased. Thus, even if TFEB relocates to the nucleus the 
effects of it are not seen as would be expected: as an increase in lysosome 
biogenesis.  
It is interesting to speculate the connection between AGU, or LSDs in general, 
and the preliminary TFEB differences seen in immunofluorescent staining. 
Actually, lysosomal storage disorders and overexpression of TFEB have been 
studied together from an enhanced exocytosis and autophagy point of view. 
Various lysosomal storage diseases have been proved to exhibit a decrease 
in the accumulated metabolic byproduct when TFEB is overexpressed. 
(Medina et al, 2011; Spampanato et al, 2013; Song et al, 2014) These studies 
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support the hypothesis of a functioning TFEB signaling pathway in lysosomal 
storage diseases, which may be suitable for therapeutic aspects in the future.  
In future experiments, it would be interesting to replicate these studies with 
another LSD primary cell line to study if the pathological state affects e.g. the 
aging cells similarly. In addition, the TFEB and lysosome localization studies 
would be intriguing to replicate in order to see if the differences between 
healthy and LSD cells remain. From therapeutic aspect, it would be beneficial 
if pathological similarities would be found and the LSDs could share a 
therapeutic approach. 
 
4.5 Western Blot  
  
Western blot analysis with anti-AGA antibody showed an increased expression 
of AGA in the AGU lymphocyte cell lysate. Aspartylglucosaminidase, the 
lysosomal enzyme responsible of the metabolism of aspartylglucosamine in 
healthy cells, is not functional in the AGU cells despite the increased 
expression. Under normal conditions, the enzyme is autocatalytically cleaved 
into its two subunits, which form the active heterotetrameric AGA-enzyme 
consisting of two alpha and two beta chains. These subunits are at 24-205 aa 
(alpha) and 206-346 aa (beta) with a signal peptide preceding the subunits. 
The anti-AGA antibody is reported to recognize the amino acids 28-245 of the 
human enzyme, of the total 346 amino acids (UniProt.org, P20933). Thus, the 
antibody recognizes the enzyme before it is cleaved into the subunits, which 
can be the underlying cause to the seemingly higher protein expression in the 
AGU cells lysates. This result is in line with the fact that the malfunctioning 
enzyme accumulates within the cell causing downstream effects in its 
secondary substrate accumulation and damaging the overall cellular function 
(Schultz et al, 2011).   
In future experiments, antibodies that recognize the different subunits should 
be used in addition to the one recognizing the entire amino acid chain.   
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4.6 Study Limitations and Conclusions  
  
The limitation of this study is the narrow patient population in terms of the origin 
of the cells used. Although both of the patient cells carry the most common 
mutation (AGUFIN major), it must kept in mind that there are other mutations 
within the AGA gene causing AGU. However, from a drug discovery 
perspective, the established patient model is good enough for a baseline, 
which can then be altered to aim for the baseline of the healthy cells, as long 
as the limitations are kept in mind. Additionally, future studies are needed with 
other LSD types before wider exploitation and generalization of these results 
to cover other LSD pathologies. 
 
As a conclusion, the characterization of the cells produced a valid efficacy 
model for future studies with various modalities within the Therapy Area Rare 
Diseases at Orion Pharma Orion Corporation. The enzyme activity 
measurements distinguished the healthy cells with a sufficient AGA activity 
from the AGU cells with an enzyme activity diminished to approximately 10% 
of the healthy cells. Corresponding to these results, the GlcNAc-Asn amount 
in the healthy cells was significantly lower than in the AGU cells where 
accumulation of the substrate was seen. With Western Blot analysis, a bigger 
amount of an uncleaved proenzyme was seen in the AGU cells compared with 
the healthy cells, in which the enzyme was presumably more effectively 
cleaved into its subunits. In immunostaining experiments, no clear difference 
was seen in the lysosome localization between the healthy and AGU cells, and 
thus, this method is still in need for optimizing of better antibodies more reliably 
recognizing lysosomal markers. TFEB staining, however, yielded interesting 
differences between the healthy and AGU cells in the subcellular localization 
and thus active state of TFEB. These optimized methods to model lysosomal 
storage diseases now allow the full utilization in studying the intervention 
options for numerous lysosomal storage diseases and thus may in the future 
play a role in alleviating the symptoms in patients affected.  
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5. Materials and methods  
  
5.1 Cell culture  
  
Fibroblasts were attained from Coriell Institute (New Jersey, USA). 
Aspartylglucosaminuria cells (GM00568) were from an 18-year-old female 
patient of Finnish origin, and the control cells (GM03651) used were gender- 
and age matched control (Female, 25 years old, Caucasian). AGU fibroblasts 
were cultured in Eagle's Minimum Essential Medium (EMEM) with Earle's salts 
supplemented with non-essential amino acids (NEAA), PenStrep, 20% Fetal 
Bovine Serum (FBS) and GlutaMAX. Control fibroblasts were cultured with the 
same medium and supplements, but only 15% FBS. Sub-culturing of the cells: 
Confluent cell culture vessels were washed with 1X DBPS (Dulbecco's 
phosphate-buffered saline) and incubated with 0.25% Trypsin until the cells 
detached. Medium was used to inactivate the trypsin before centrifugation (110 
g for 10 minutes at RT). The cells were reseeded at approximately 1.0*104 
cells/cm2 once or twice per week in NuncTM T75 cell culture vessels. Refer to 
table 1 for details of materials used in cell culture. 
Lymphoblasts were attained from Coriell Institute (New Jersey, USA). Cells 
from healthy individual (GM07521, 19 years old, Female, Caucasian) and AGU 
patient (GM10417, 14 years old, Female, Caucasian (Finnish)) were both 
grown in RPMI 1640 medium with L-Glutamine supplemented with PenStrep 
and 15% FBS. The cells growing in suspension were reseeded at 
approximately 2*105 cells/ml twice per week in NuncTM T25 cell culture vessels.  
Detaching the fibroblasts for sub culturing proved to be very inefficient with the 
instructions provided by the supplier. The protocol was optimized with 0.04%, 
0.08%, 0.16% and 0.25% trypsin in 0.53 mM EDTA in HBSS. Different 
detachment methods were tested parallel to make sure the phenotype of the 
cell culture was not altered. In addition to the detachment methods, different 
culture vessels with different coatings were tested. Based on the outcomes 
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after four weeks of parallel culture methods, a DPBS wash prior to detaching 
the cells with 0.25% trypsin was introduced.  
  
Table 1. Materials used in cell culture  
Material  Supplier  Catalog  
#  
DPBS  GibcoTM, ThermoFisher 
Scientific  
14190- 
094  
EMEM  Cell  Culture  
Medium  
Sigma-Aldrich  M2279- 
500ML  
EDTA 
(Ethylenediaminetetraacetic 
acid) 
 
Sigma-Aldrich 60-00-4 
FBS  Sigma-Aldrich  F7524  
GlutaMAXTM  GibcoTM, ThermoFisher 
Scientific  
35050- 
038  
HBSS  GibcoTM, ThermoFisher 
Scientific  
14065- 
049  
MEM NEAA   GibcoTM, ThermoFisher 
Scientific  
11140- 
035  
NuncTM EasYFlaskTM  75 cm2 
NunclonTM Delta Surface  
ThermoFisher Scientific  156499  
NuncTM EasYFlaskTM  25 cm2 
NunclonTM Delta Surface  
ThermoFisher Scientific  156367  
PenStrep  GibcoTM, ThermoFisher 
Scientific  
15140- 
122  
RPMI-1640  GibcoTM, ThermoFisher 
Scientific  
A10491- 
01  
Trypsin (0.5% Trypsin- 
EDTA)  
GibcoTM, ThermoFisher 
Scientific  
15400- 
054  
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5.2 Starvation   
  
Starved cells were used in immunofluorescent imaging and LysoTracker time 
series experiment. The fibroblasts used for these experiments were plated at 
least one day prior to starting the study with a confluency of 5000 cells / well 
on a tissue culture 96-well plate treated with a tissue culture (TC) -coating 
(CellCarrierTM-96 Ultra, PerkinElmer, 6055300). The normal growth medium 
was removed by aspiration and the pre-heated starvation medium (normal 
medium depleted of FBS, containing either 0% of 5% FBS, depending on the 
study) was pipetted onto the cells. Control cells were treated similarly. 
Starvation medium was supplemented with GlutaMAX, NEAA and PenStrep at 
all times, excluding the TFEB staining, where the media was deprived of NEAA 
in addition to FBS.  
  
5.3 Cell lysate for enzyme activity measurement  
  
Cell lysates were prepared from both AGU and healthy lymphocytes. 
Approximately 60 million cells were centrifuged for 10 minutes x 120 g at RT. 
The pellet was resuspended in approximately 500 ul of 0.1% TritonX-100 
(TritonTM X-100, Sigma-Aldrich, X-100-100ML) in DPBS. Three freeze-thaw 
cycles with vortexing were used to lyse the cells. The cell suspension was 
frozen on dry ice and then thawed in warm water bath coupled with vortexing. 
After freeze-thawing, the lysate was centrifuged for 10 minutes x 10 000 g at 
+4C. The supernatant was collected and stored in -20C until further analysis.  
  
5.4 Enzyme activity measurement  
  
Enzyme activity was measured from cell lysates from lymphocytes (described 
above). Tris-HCl buffer with 1% ethylene glycol (Sigma-Aldrich, 107-21-1) was 
used as buffer, pH adjusted to 7.5. L-Aspartic acid β 7-amido-4-
methylcoumarin (Asp-AMC, Sigma-Aldrich, A1057) was used as substrate. 
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The substrate was weighted and diluted to DMSO to make 10 mM stock. The 
stock was further diluted to the buffer to make 800 µM working dilution. 7-
Amino-4-methylcoumarin  
(AMC, Sigma-Aldrich, 257370) was used as a standard. Standard was 
weighted and 50 mM stock was made in Dimethyl Sulfoxide (DMSO, Sigma-
Aldrich, D2650-50ML).   
¼ (25 µl) cell lysate or buffer, ¼ (25 µl) Asp-AMC or buffer and ½ (50 µl) buffer 
was pipetted onto a 96well plate (Cliniplate, ThermoFisher Scientific, 
9502227). Dilutions of 1:2 starting from 1000 nM were used for standard curve 
establishment (200 µl per well).   
Absorbance was measured with EnSpireTM Microplate Reader 23001365 with 
software EnSpire® 4.1. Baseline measurement was performed directly after 
substrate addition, excitation 360 and emission 460. The plate was kept 
covered in 37 C and enzyme activity was measured again after 24 hours.   
The same method was used to measure the activity of a commercially available 
recombinant enzyme (Recombinant Human AGA Protein, Novus Biologicals, 
NBP2-52631). Tris-HCl buffer supplemented with 1% ethylene glycol was used 
as the buffer, Asp-AMC prepared fresh to DMSO was used as the substrate and 
AMC dilution series for the standard curve measurement. The recombinant 
enzyme was diluted to the buffer to make 10 µg/ml dilution, and further 
combined with 80% buffer, and 10% Asp-AMC, which was added just before 
measurement to make a final concentration of the recombinant enzyme to 1 
µg/ml as highest. Dilution series for the recombinant enzyme was prepared to 
start from 1 µg/ml with 1:3 dilutions. The activity was measured with EnSpireTM 
Microplate Reader 23001365 with software EnSpire® 4.1. for two hours at RT, 
imaged every two minutes with shaking in between the measurements. 
Excitation of 360 nm and emission of 460 nm was used for all enzyme activity 
measurements.  
Km values of AGA were defined for healthy lymphocytes with a substrate 
dilution series and a standard curve. 7-Amino-4-methylcoumarin (AMC, 
SigmaAldrich, 257370) diluted to DMSO to 50 mM was used as a standard 
and Michaelis-Menten equation was used to calculate the Km values.  
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Visual assessment and Shapiro-Wilk test were used to check the normality of 
data. After this, for all of the enzyme activity measurement results, two-sample 
t-test with assumption for normality was done to test for statistical significance. 
The same test was done in the analysis of GlcNAc-Asn amount, although 
normality could not be checked due to small number of replicates. P-value 
<0.05 was considered significant. 
All calculations and figures were done with GraphPad Prism (8.0.2 (263)). 
Mean and SD shown on each graph.  
  
5.5 Immunofluorescence  
  
For immunofluorescence staining, the cells were washed 5 min with DPBS 
before fixation with 3.7% formaldehyde in DPBS for 20-30 minutes in RT. 
Sequentially, the cells were then washed twice with DPBS for 5 minutes 
followed by blocking in 10% FBS, 0.1% TritonX-100 or 1% saponin (Sigma-
Aldrich, 8047-15-2), 1% Bovine Serum Albumin (BSA, Sigma-Aldrich, A2153-
100G) in DPBS for 45-60 minutes in RT. After blocking, the cells were washed 
with 1% serum, 0.1% TritonX-100 or 1% saponin, 1% BSA in DPBS once 
before using the same solution in primary antibody mixture. Primary antibodies 
were incubated O/N in +4 C. Refer to table 2 for antibody dilutions used. 
The cells were washed three times 5 minutes with 1% BSA in DPBS. 
Secondary antibody was diluted to 1% BSA in DPBS and incubated on cells 
for 1 h in RT. Together with secondary antibody, Phalloidin was added onto 
the wells in order to detect the cytoskeleton. For the last 5 minutes, 1:1000 
DAPI was added to the secondary antibody solution. After secondary antibody 
incubation, the cells were washed for 5 minutes each, 2-3 times with DPBS 
and 1-2 times with phosphate buffer (0.01 M NaH2PO4 and 0.01 M Na2HPO4 
in dH2O). The last wash was left on and the plate was imaged with Operetta 
CLSTM, PerkinElmer, and with the Harmony software (PerkinElmer, 
4.9.2137.273). The images were exported and analyzed with Columbus 
(Columbus, 2.8.2.1205, PerkinElmer).  
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When no primary antibodies were used for fibroblast staining, the protocol was 
started from the blocking after fixation of the cells, and the plate was washed 
once with 1% BSA in DPBS before incubations with phalloidin and DAPI.  
Washing and imaging the plate was done as when using primary antibodies.   
For statistical analysis of the positioning of lysosomes, normality of data was 
checked both visually and with Shapiro-Wilk test. For normally distributed data, 
one-way ANOVA was used to conduct statistical analysis for all sample 
groups. In cases data was not normally distributed, Mann-Whitney test was 
conducted and the groups were analyzed pair-wise. P-value <0.05 was 
considered significant. 
Table 2. Antibodies and fluorescent stains used in immunostaining and 
Western Blot analysis.  
Immunofluorescence antibodies   
Primary  Anti-LAMP-1  Novus  
biologicals  
NB120-19294  1:500  
  Anti-TFEB  Abcam  ab220695  1:500  
 Secondary DAPI   Sigma-Aldrich  D9542 1 mg/ml, 
further diluted  
1:1000  to  
wells  
 Goat  anti-rabbit  
Ig-G Alexa 488  
InVitrogen  A11034 1:400  
  LysoTracker™  
Deep Red  
InVitrogen  L12492  75 uM   
  Phalloidin, Alexa  
Fluor® 568  
InVitrogen   A12380  1:400  
Western Blot antibodies     
 Primary Anti-AGA  Novus  
Biologicals  
NBP1-79881  1:1000   
  Anti-AGA  Novus  
Biologicals  
NBP1-88866  1:1000   
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  Anti-AGA  Abcam  ab231021  1:1000   
 Anti-Vinculin  Abcam  ab129002  1:10 000   
Secondary  Goat  anti-rabbit  
IgG-HRP  
BioRad  #1706515  1:3000   
  Precision Protein  
StrepTactin-HRP  
Conjugate  
BioRad  #161-0380  1:5000  
  
  
5.6 Cell lysate and protein measurement for Western Blot  
  
Cell samples for western blot analysis were prepared by lysing the cells using 
MPER buffer (Thermo Fisher, #78501) supplemented with 4% protease 
inhibitor solution (Complete EDTA-free, Roche, #11873580001 in Milli-Q) and 
10% phosphatase inhibitor solution (PhosSTOP, Roche, #04906837001 in M-
PER buffer; Thermo Fisher, #78501).  
Protein concentration of the cell lysates was determined with Micro BCA 
Protein Assay Kit (Thermo Scientific, #23235) according to the manufacturer’s 
instructions. The luminescence was measured with EnSpireTM Microplate 
Reader 23001365 with software EnSpire® 4.1.  
  
5.7 Western Blot  
  
Western blot samples were prepared for the polyacrylamide gel 
electrophoresis by thawing the samples on ice. Then 4 x Laemmli loading 
buffer (BioRad #1610747, completed with 10% β-mercaptoethanol) and an 
appropriate amount of Lysis buffer was pipetted to an Eppendorf tube together 
with an appropriate amount of the cell lysate to equal 30 µg of protein per well.   
The samples were boiled at 95 C for five minutes and centrifuged 10 000 x g 
for 10 s.   
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7 µl of MW standard (BioRad, Precision plus proteinTM WesternCTM Blotting 
Standards, #161-0376) and 40 µl of samples were pipetted to the gel (BioRad 
Criterion TGX Stain-free 4-15%, #5678083) after filling the running chamber 
and rinsing the wells with 1 X Tris/Glysine/SDS buffer (BioRad, #161-0772). 
The gel was run with 100-120V for 60-120 minutes, until the smallest samples 
were at the bottom of the gel.   
After the run, the gel was transferred to transfer buffer and onto the blotting 
membrane (BioRad Trans-Blot Turbo Midi Nitrocellulose, #1704159) and after 
constructing the sandwich, blotted with Trans-Blot Turbo Mixed MW>150, for 
7 minutes. After blotting, the membrane was cut to appropriate sizes for 
continuation with antibody staining.   
The membrane was blocked in 5% milk (Blotting Grade Blocker, BioRad, 
1706404), 0.1% Tween-20 in 1 X TBS (TBS TweenTM-20, ThermoFisher 
Scientific, 28360)  for 1 h on a tilter.   
Primary antibody was diluted to the blocking buffer and the membrane was 
incubated O/N in +4 C on a tilter. Refer to table 2 for antibodies and dilutions 
used.  
After primary antibody incubation, the membrane was rinsed trice with TBST 
and washed 3 x 5 minutes on a tilter in RT. The secondary antibody dilution 
was made in the same buffer as the primary antibody dilution. Wash solution 
was removed before addition of the secondary antibody dilution (Goat anti-
rabbit IgG-HRP, BioRad, #1706515, 1:3000) and StrepTactin (Precision 
Protein StrepTactin-HRP Conjugate, #161-0380, 1:5000), and the membrane 
was incubated for 1-2 h on a tilter, protected from light at RT.   
The membrane was then rinsed 3 x and washed 3 x 5 minutes with TBST on 
a tilter, protected from light at RT. ECL (BioRad #1705061) 1:1 was used for 
detection: excess buffer was dried off membrane and ECL was pipetted onto 
the membrane. The membrane was incubated 2 minutes protected from light 
and imaged with Azure Biosystems c400 and cSeries Capture Software 
1.9.2.0315.   
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The band intensity was determined with ImageJ software version 1.52a 
(Wayne Rasband, National Institutes of Health, USA). The target 
protein/loading control ratio was determined for both healthy and AGU AGA 
bands. The ratio was further normalized to the intensity of the band of healthy 
cells, which could be used to determine the increased intensity for the AGU 
cell band.   
  
5.8 LysoTracker  
  
Lysosomes were labelled with LysoTracker DeepRed (InVitrogen, #L12492). 
The 1 mM stock was diluted to cell growth medium to make a 10 µM working 
stock. This stock was further diluted to growth medium to the desired dilution 
of 75 nM. Growth medium of the plated cells was aspirated and pre-warmed 
medium with dye was pipetted onto the cells with as little light as possible. The 
cells were incubated with the dye in 37°C for 30 minutes after which the 
medium was changed. The plates were then either imaged with appropriate 
excitation and emission wavelengths for the dyes or the plate was fixed and 
stained according to the chapter 7.5 above.   
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7. Abbreviations list  
  
AGA    Aspartylglucosaminidase  
AGU    Aspartylglucosaminuria  
BBB    Blood-Brain Barrier  
BMT    Bone Marrow Transplantation  
CI-MPR    Cation-Independent Mannose-6-Phosphate Receptor  
CLEAR    Coordinated Lysosomal Expression and Regulation  
CNS    Central Nervous System  
CD-MPR    Cation-Dependent Mannose-6-Phosphate Receptor  
EE    Early Endosome  
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EMA    European Medicines Agency  
ER    Endoplasmic Reticulum  
ERT    Enzyme Replacement Therapy  
FDA    U.S. Food and Drug Administration  
GlcNAc-Asn  Aspartylglucosamine    
IGF-II    Insulin-like Growth Factor Receptor  
LAMP-1    Lysosome Associated Membrane Protein 1  
LE    Late Endosome  
LSD    Lysosomal Storage Disease  
M6P    Mannose-6-phosphate  
MPR    Mannose-6-phosphate receptor  
mTOR    Mechanistic Target of Rapamycin  
SNARE  N-ethylmaleimide-Sensitive Factor-Attachment Protein  
Receptor  
 
SRT    Substrate Reduction Therapy  
TFEB    Transcription Factor EB  
TGN    Trans-Golgi-Network  
V-ATPase   
  
ATP-Dependent vacuolar proton pump  
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